T
13.48
0.88 (6.98%)
| Previous Close | 12.60 |
| Open | 12.89 |
| Volume | 2,307,590 |
| Avg. Volume (3M) | 1,331,543 |
| Market Cap | 1,031,105,408 |
| Price / Sales | 7.06 |
| Price / Book | 76.10 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -172.75% |
| Operating Margin (TTM) | -89.07% |
| Diluted EPS (TTM) | -4.52 |
| Quarterly Revenue Growth (YOY) | 69.60% |
| Total Debt/Equity (MRQ) | 2,662.08% |
| Current Ratio (MRQ) | 1.71 |
| Operating Cash Flow (TTM) | -272.23 M |
| Levered Free Cash Flow (TTM) | -214.69 M |
| Return on Assets (TTM) | -26.14% |
| Return on Equity (TTM) | -279.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Travere Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 3.0 |
| Insider Activity | -2.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 99.13% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (Scotiabank, 100.30%) | Buy |
| 27.00 (Wells Fargo, 100.30%) | Buy | |
| Median | 24.50 (81.75%) | |
| Low | 20.00 (Barclays, 48.37%) | Buy |
| Average | 24.00 (78.04%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 17.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 14 Nov 2024 | 22.00 (63.20%) | Hold | 18.47 |
| Barclays | 01 Nov 2024 | 20.00 (48.37%) | Buy | 17.57 |
| Scotiabank | 01 Nov 2024 | 27.00 (100.30%) | Buy | 17.57 |
| 16 Oct 2024 | 23.00 (70.62%) | Buy | 18.05 | |
| Wells Fargo | 21 Oct 2024 | 27.00 (100.30%) | Buy | 18.10 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| INRIG JULA | - | 18.79 | -2,506 | -47,197 |
| Aggregate Net Quantity | -2,506 | |||
| Aggregate Net Value ($) | -47,197 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 18.79 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| INRIG JULA | Officer | 06 Jan 2025 | Automatic sell (-) | 440 | 18.71 | 8,232 |
| INRIG JULA | Officer | 03 Jan 2025 | Sell (-) | 2,066 | 18.86 | 38,965 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |